The Effects of Bromelain Supplementation on Clinical Outcomes, Inflammatory and Oxidative Stress Biomarkers in Patients With Traumatic Brain Injury: A Randomized, Double‐Blind Placebo‐Controlled Clinical Trial
Open Access
- 29 July 2026
- journal article
- research article
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (8) , e70162
Abstract
Traumatic brain injury (TBI) is the leading cause of death from injury. Many studies have shown that cytokines, chemokines, and oxidative stress play a crucial role in the pathophysiology of TBI. One of the types of interventions that are receiving more and more attention is nutritional support and the use of nutritional supplements to reduce inflammation in these patients. The present study was a double‐blind controlled clinical trial, performed on patients with traumatic brain injury. Patients in the intervention group received 600 mg of oral bromelain daily through gavage, while the patients in the control group received a placebo for 14 days. SOFA, APACHE, and NUTRIC scores were evaluated at each time of blood sampling and 28‐ and 60‐day mortality. Also, clinical and biochemical information (CRP, MDA, IL‐6, and TAC), anthropometry, and nutritional information of patients were recorded during the study. There was no significant difference between the two groups in terms of gender, weight, BMI, MAC, APACHE SCORE, NUTRIC SCORE, SOFA SCORE, and energy intake at the beginning of the study ( p > 0.05). Bromelain supplementation significantly reduced IL‐6 levels ( p < 0.001), APACHE score ( p = 0.011), SOFA score ( p < 0.001), and NUTRIC score ( p < 0.001). Furthermore, 60‐day mortality was significantly lower in the bromelain group compared to the placebo group ( p = 0.036). However, there was no significant effect on CRP ( p = 0.377), MDA ( p = 0.061), TAC levels ( p = 0.185). Bromelain supplementation significantly improved IL‐6 levels, APACHE, SOFA, and NUTRIC scores, and reduced 60‐day mortality in patients with traumatic brain injury. However, its effects on CRP, MDA and TAC levels were not statistically significant. These findings suggest that bromelain may serve as a promising adjunctive therapy to reduce inflammation and improve clinical outcomes in critically ill TBI patients. Further studies with larger sample sizes and longer follow‐up periods are needed to confirm these results.Keywords
This publication has 30 references indexed in Scilit:
- Bromelain supplementation and inflammatory markers: A systematic review of clinical trialsClinical Nutrition ESPEN, 2023
- High dose vitamin D improves total serum antioxidant capacity and ICU outcome in critically ill patients - A randomized, double-blind clinical trialEuropean Journal of Integrative Medicine, 2021
- Combined anthocyanins and bromelain supplement improves endothelial function and skeletal muscle oxygenation status in adults: a double-blind placebo-controlled randomised crossover clinical trialBritish Journal of Nutrition, 2020
- Improved WOMAC score following 16-week treatment with bromelain for knee osteoarthritisClinical Rheumatology, 2016
- The Role of Serial Oxidative Stress Levels in Acute Traumatic Brain Injury and as Predictors of OutcomeWorld Neurosurgery, 2016
- Involvement of Pro- and Anti-Inflammatory Cytokines and Chemokines in the Pathophysiology of Traumatic Brain InjuryNeurotherapeutics, 2010
- The relationship between nutritional intake and clinical outcomes in critically ill patients: results of an international multicenter observational studyIntensive Care Medicine, 2009
- Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitroClinical Immunology, 2008
- Genotoxicity of advanced glycation end products in mammalian cellsCancer Letters, 2003
- Bromelain: biochemistry, pharmacology and medical useCellular and Molecular Life Sciences, 2001